Chong Kun Dang’s antihypertensive Dilatrend sales top 66 billion won
Published: 2011-01-19 07:00:00
Updated: 2011-01-19 07:00:00
Pfizer’s Norvask (amlodipine mesilate) has boasted the highest annual revenue in Korea’s competitive hypertensive market for the past years. But last year, the company’s flagship product is being challenged by Chong Kun Dang Pharmaceutical’s Dilatrend (carvedilol).
Chong Kun Dang said the acc...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
